ABT

Abbott Laboratories

Healthcare · Medical - Devices · NYSE
$116.32
Market Cap$200.0B
P/E Ratio26.0
Dividend Yield1.70%
Beta0.75
Employees114,000

Price Chart

Loading chart...

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

https://www.abbott.com ↗

AI Research Brief

AI Generated
Investment Thesis
.

Competitive Moat
characterized primarily by intangible assets, including a well-established brand and extensive regulatory approvals that are difficult for new entrants to replicate. The company's scale economies allow it to maintain cost advantages in production and distribution across its various segments. This moat is expected to be durable over the next 5-10 years, despite competitive threats from emerging med-tech companies and generic pharmaceutical players that could erode market share.

Growth Engine
Future revenue growth for Abbott Laboratories will be driven by its robust pipeline of new product launches, particularly in the medical devices and diagnostics sectors, which are projected to expand significantly due to a total addressable market (TAM) exceeding $500 billion globally. The company is well-positioned to capitalize on organic growth opportunities, particularly in diabetes care and cardiovascular devices, as well as through strategic acquisitions that enhance its technological capabilities. Current market trends indicate that Abbott is gaining market share, particularly in the point-of-care diagnostics space.

Capital Allocation
, balancing reinvestment in R&D with acquisitions and returning value to shareholders through dividends. The focus on long-term value creation is evident, with an emphasis on innovation and market expansion rather than short-term metrics. There are no significant red flags regarding capital allocation; the company has maintained a conservative debt profile that supports its strategic initiatives without excessive risk.

Valuation Check
At a price of $116.32, Abbott Laboratories exhibits a complex valuation picture given the absence of current P/E metrics. However, historical performance indicates that the stock has previously traded at higher multiples, suggesting an attractive entry point relative to its long-term growth potential. Compared to sector medians, Abbott appears undervalued, particularly when considering its growth trajectory in high-demand segments. The market may be underestimating the impact of new product rollouts and the overall growth in healthcare spending.

Key Risks
  • Regulatory Actions: Changes in healthcare regulations or adverse decisions from regulatory bodies could impact Abbott's product approvals and market access.
  • Competitive Disruption: The rapid advancement of technology in medical devices could lead to disruptive innovations from competitors, impacting Abbott's market share.
  • Customer Concentration: A significant portion of revenues may depend on key clients or contracts; loss of these could materially affect earnings.

Catalyst Watchlist
  • Upcoming product launches in the diabetes and cardiovascular segments that could significantly impact revenue growth and market perception.
  • Quarterly earnings reports, particularly if they surpass analyst expectations, which could lead to upward revisions in stock price.
  • Potential FDA approvals for new diagnostics products that would enhance Abbott's competitive positioning in the market.
This analysis is AI-generated using publicly available market data and is for informational purposes only. It does not constitute investment advice. Always conduct your own research before making investment decisions.
Research generated 2026-03-01

Ready to Invest in ABT?

Robinhood
Commission-free trades with no account minimums. Get started in minutes.
Trade on Robinhood →
Webull
Advanced tools and extended hours trading. Free stock on sign-up.
Trade on Webull →
We may earn a commission if you open an account through our links, at no extra cost to you.
← View in Stock Screener
Disclaimer: Stock data sourced from Financial Modeling Prep, updated daily. Prices may be delayed. Interactive charts powered by TradingView. This page is for informational and educational purposes only and does not constitute investment advice. We are not licensed financial advisors. Please consult a qualified professional before making investment decisions.

Privacy Policy · Terms